We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective.
- Authors
Orozco-Leal, Giovany; Johnson, Eugenie Evelynne; Hosseinijebeli, Sedighe; Robinson, Tomos; Homer, Tara; Eastaugh, Claire H.; Richmond, Catherine; Tanner, Louise; Meader, Nick; Kenny, Ryan; Wallace, Sheila A.; Rice, Stephen
- Abstract
This article discusses the challenges of modeling long-term survival in health economic decision models for cancer treatments. Specifically, it focuses on the use of a cure assumption in the context of neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC) using nivolumab and chemotherapy. The article explores different methods of long-term survival modeling, such as flexible parametric models, cure models, mixture models, and landmark models. It also highlights the importance of conducting scenario analyses and considering statistical models that account for cure in a proportion of patients. The article concludes by emphasizing the need for adequate evidence and justification when implementing a cure assumption in economic models and suggests that fitting cure models could be beneficial in certain cases.
- Subjects
NON-small-cell lung carcinoma; NEOADJUVANT chemotherapy; NIVOLUMAB
- Publication
PharmacoEconomics, 2024, Vol 42, Issue 2, p133
- ISSN
1170-7690
- Publication type
Article
- DOI
10.1007/s40273-023-01328-w